Published in Clin Cancer Res on June 06, 2012
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest (2015) 1.11
WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer (2014) 1.05
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget (2013) 0.92
Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget (2015) 0.91
Biological determinants of bladder cancer gene expression subtypes. Sci Rep (2015) 0.90
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. J Immunother Cancer (2015) 0.88
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. J Invest Dermatol (2015) 0.88
Molecular and genetic diversity in the metastatic process of melanoma. J Pathol (2014) 0.86
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. J Invest Dermatol (2014) 0.84
The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell Melanoma Res (2014) 0.83
Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. Oncotarget (2015) 0.83
BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol (2014) 0.81
Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability. Clin Transl Med (2013) 0.80
A protein deep sequencing evaluation of metastatic melanoma tissues. PLoS One (2015) 0.77
Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med (2014) 0.77
Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. Oncotarget (2016) 0.76
Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours. PeerJ (2015) 0.75
Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass. J Invest Dermatol (2014) 0.75
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Med Genomics (2015) 0.75
Host kinin B1 receptor plays a protective role against melanoma progression. Sci Rep (2016) 0.75
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res (2008) 54.83
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene (2011) 2.49
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res (2011) 1.87
High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene (2007) 1.83
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 1.74
BRCA1 is a new MITF target gene. Pigment Cell Melanoma Res (2011) 1.47
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40
DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res (2007) 1.30
Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res (2010) 1.09
Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg (2011) 0.92
Cutaneous melanoma: fishing with chips. Curr Mol Med (2008) 0.81
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol (2002) 6.35
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell (2006) 4.01
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol (2005) 3.72
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Malignant melanoma--diagnosis, treatment and follow-up in Norway. Tidsskr Nor Laegeforen (2013) 3.21
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
GOBO: gene expression-based outcome for breast cancer online. PLoS One (2011) 2.81
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol (2008) 2.67
Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics (2008) 2.66
A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol (2002) 2.66
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol (2010) 2.49
Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis (2005) 2.47
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malmö Diet and Cancer cohort. Am J Clin Nutr (2007) 2.38
A molecular taxonomy for urothelial carcinoma. Clin Cancer Res (2012) 2.37
Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat (2007) 2.35
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer (2007) 2.34
Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol (2008) 2.33
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol (2009) 2.32
Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A (2013) 2.32
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet (2011) 2.24
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer (2012) 2.16
Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci U S A (2003) 2.10
MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer (2009) 2.06
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
Genetic alterations in signaling pathways in melanoma. Clin Cancer Res (2006) 2.00
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res (2010) 1.99
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res (2010) 1.97
Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest (2011) 1.96
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res (2010) 1.94
Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res (2002) 1.93
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res (2003) 1.89
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res (2006) 1.87
Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene (2004) 1.83
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol (2007) 1.83
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer (2002) 1.81
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol (2009) 1.81
The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res (2003) 1.81
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res (2005) 1.80
p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol (2011) 1.77
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One (2012) 1.76
Changes in tree growth, biomass and vegetation over a 13-year period in the Swedish sub-Arctic. Ambio (2011) 1.75
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75
Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis. Arthritis Rheum (2011) 1.74
Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood (2007) 1.73